Vision Loss News and Research

RSS

Hawaii surgeons successfully implant FDA-approved eye telescope for AMD

A team of surgeons from Hawaii, Dr. Michael Bennett of Retina Institute of Hawaii and Dr. Michael McMann of McMann Institute, has successfully implanted the FDA-approved eye telescope, a first in Hawaii, at one of the leading medical centers in Honolulu.

19 Jan 2012

Vitamin D could prevent age related eye degeneration: Study

A new study showed that increased vitamin D intake can help to prevent age-related diseases, in particular loss of vision and blindness.

18 Jan 2012

Georgia Tech findings advance glaucoma research

Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's permanent. New findings at Georgia Tech, published in January during Glaucoma Awareness Month, explore one of the many molecular origins of glaucoma and advance research dedicated to fighting the disease.

18 Jan 2012

New computational modeling methods book for ophthalmologists

Dr. Sumeet Dua, the Upchurch Endowed Professor of Computer Science and coordinator of information technology research at Louisiana Tech University, has co-edited a new book on computational modeling methods that can help ophthalmologists develop innovative computer systems to provide critical support and better care options for patients.

18 Jan 2012

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

Genentech, a member of the Roche Group, today announced it will make its first milestone payment to ForSight VISION4, Inc. as part of an exclusive license agreement to develop the company's investigational drug delivery device, designed to provide sustained delivery of Lucentis (ranibizumab).

13 Jan 2012

Grapes offer dramatic protection against age-related macular degeneration

Can eating grapes slow or help prevent the onset of age-related macular degeneration (AMD), a debilitating condition affecting millions of elderly people worldwide? Results from a new study published in Free Radical Biology and Medicine suggest this might be the case. The antioxidant actions of grapes are believed to be responsible for these protective effects.

12 Jan 2012

Middle-aged adults with diabetes have time to learn how to control hypertension

A new study suggests that middle-aged adults recently diagnosed with diabetes and hypertension have time to try to learn how to control their high blood pressure without medications, but not too much time.

9 Jan 2012

Dendrimers offers a new way to treat age-related macular degeneration, retinitis pigmentosa

Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A study by investigators at Mayo Clinic, Wayne State University and Johns Hopkins Medicine shows that steroids attached to the dendrimers target the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.

14 Dec 2011

Potential nanoparticle treatment for macular degeneration and retinitis pigmentosa

Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A collaborative research study among investigators at Wayne State University, the Mayo Clinic and Johns Hopkins Medicine shows that steroids attached to the dendrimers targeted the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.

14 Dec 2011

Post-baseline vision data from Lundbeck's Sabril patient registry presented at AES meeting

Post-baseline vision data from Lundbeck's Sabril patient registry is available for the first time today as a late-breaking poster presentation at the annual meeting of the American Epilepsy Society.

5 Dec 2011

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Mayo Clinic researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis (MS). The findings could lead to better care for the thousands of patients around the world with NMO. The paper was published in the journal, Proceedings of the National Academy of Sciences, USA.

3 Dec 2011

Regeneron’s Eylea for treating age related macular degeneration gets FDA nod

Regeneron Pharmaceuticals has received marketing approval for their eye drug - Eylea, an injection meant to treat a common cause of blindness in older people. Eylea can be used to treat “wet” age-related macular degeneration. The only other drug approved for the condition is Lucentis from Roche, which was approved in 2006.

21 Nov 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.

19 Nov 2011

Regeneron receives FDA approval for Eylea to treat wet AMD

The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.

18 Nov 2011

Lower glycemic index diet may delay onset of AMD-like lesions

Feeding older mice a lower glycemic index (GI) diet consisting of slowly-digested carbohydrates delays the onset of age-related, sight-threatening retinal lesions, according to a new study from the Laboratory for Nutrition and Vision Research at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University.

14 Nov 2011

GHSU expert to again coordinate two national diabetes initiatives

Two national efforts supporting diabetes research will again be coordinated by a Georgia Health Sciences University bioinformatics expert.

10 Nov 2011

National lupus organizations urge NICE to recommend Benlysta for coverage

National lupus organizations in more than 28 countries, and individuals with lupus and their families around the world, are rallying to protect access to new treatments and the development of future therapies to treat lupus.

1 Nov 2011

Mayo Clinic, Oxford BioMedica collaborate to develop gene therapy for glaucoma

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that it has entered into a research and development collaboration with Mayo Clinic, Rochester (USA) to develop a novel gene therapy for the treatment of chronic glaucoma.

31 Oct 2011

Zeaxanthin reduces risk for AMD

St. Louis-based ZeaVision, LLC announced that three recent groundbreaking studies demonstrate that Zeaxanthin (zee-uh-zan-thin), the predominate protective pigment in the back of the eye, reduces the risk for Age-Related Macular Degeneration (AMD) and benefits the treatment of advanced AMD, a condition that destroys central vision and affects millions of Americans.

24 Oct 2011